Standards; Chiral Molecules; Pharmaceutical/API Drug Impurities/Metabolites;
應(yīng)用:
2-[(2-Pyrazinylcarbonyl)-Bortezomib is a derivative of Bortezomib (B675700) which is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. Bortezomib is a reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells.
?您的位置：
